Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25530147 | 0.94 | PKM (0.40) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL25564438 | 0.85 | CNR2 (0.39) | PDK2PDK1KMT2ABRD4 | |
| SCHEMBL25660320 | 0.81 | SMN1; SMN2 (0.41) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL25562702 | 0.80 | PDK2 (0.38) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL22303968 | 0.80 | PDK2 (0.41) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL17437926 | 0.79 | HCAR3 (0.41) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL4043341 | 0.79 | KMT2A (0.43) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL23135531 | 0.77 | BRD4 (0.40) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL17437902 | 0.77 | F2 (0.46) | PDK2PDK1SMN1; SMN2GAAPKM | |
| SCHEMBL25522013 | 0.75 | PKM (0.42) | PDK2PDK1SMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | PDK2 2452/4885PDK1 2825/4885SMN1; SMN2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.